Categories: Acquisition

Emami raises Rs. 900 cr to part-fund Kesh King acquisition

Deal to bring in Kesh King-branded ayurvedic hair oil, capsules and shampoo formulations

Kolkata, June 20, 2015:

FMCG player Emami Ltd has raised around Rs. 900 crore debt to partially fund the Rs. 1,651-crore acquisition of Kesh King hair-care branded products from Sanjev Juneja of SBS Biotech.

This is the biggest deal for Emami so far. Earlier, it had acquired the controlling stake in Zandu Pharmaceuticals for around Rs. 700 crore.

“We have raised Rs. 800-900 crore through fresh borrowings. The balance is financed through internal resources,” Harsh Agarwal, Director, told BusinessLine .

Boost to bottom-line

The deal has brought in Kesh King-branded ayurvedic hair oil, capsules and shampoo formulations into the Emami-fold. Kesh Pari hair oil, an associate fighter brand, was also a part of the deal.

Justifying the high cost acquisition, Agarwal maintained that Kesh King products have a higher profit margin when compared to the existing products of Emami.

So far, the FMCG major’s portfolio (hair-care) include the “Navratna Cool Oil” and “Seven Oils in One” (a hair damage control offering).

The hair oil from Kesh King will be more or less similar to Emami’s Seven Oils offering, sources said.

But, according to Agarwal, Kesh King’s products are priced “higher”.

With ayurvedic only offerings in what the company calls an “affordable segment”, the brand competes with the likes of “Sesa” and “Anoop” in the hair oil segments.

Companies like Biotique, compete in the premium segment of the market with similar offerings across shampoos, hair-oils and conditioners.

National presence

According to Agarwal, these medicinal products have a strong presence in the northern and western regions.

The focus will be to expand the brand’s presence in eastern and southern regions by leveraging Emami’s distribution network. There would be no price revision either, he confirmed. The acquisition does not include takeover of any manufacturing facility.

Products will, at present, be sourced from SBS Biotech’s facility.

“We have decided to go in for contract manufacturing. However, we have an option of manufacturing the products in future,” he said.

There, however, are no “immediate” plans to re-brand Kesh King.

According to Agarwal, it will take some time before the company takes a call on the matter. Business Line

The Pharma Times News Bureau

Recent Posts

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

16 hours ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

16 hours ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

2 days ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

5 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

6 days ago